Sugi Predict

Sugi Predict / Compounds / SCHEMBL14739864

SCHEMBL14739864

SCHEMBL14739864

CCOC(=O)/C(Cl)=C/O.[KH]

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPSR1 Q6W5P4 3/20 0.43
▸ GLO1 Q04760 1/20 0.43
▸ ALDH1A1 P00352 5/20 0.40
▸ LMNA P02545 3/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ CYP2D6 P10635 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ TSHR P16473 1/20 0.38
▸ MEN1 O00255 3/20 0.37
▸ KMT2A Q03164 3/20 0.37
▸ ALOX15 P16050 1/20 0.37
▸ MGAM O43451 1/20 0.37
▸ GAA P10253 1/20 0.37
▸ SI P14410 1/20 0.37
▸ MGAM2 Q2M2H8 1/20 0.37
▸ SOAT1 P35610 1/20 0.37
▸ EGLN1 Q9GZT9 1/20 0.36
▸ CYP2C9 P11712 2/20 0.36
▸ HCAR2 Q8TDS4 1/20 0.35
▸ MAPT P10636 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14739866 1.00 NPSR1 (0.43) NPSR1GLO1ALDH1A1LMNAHSD17B10
SCHEMBL3710531 0.98 — —
SCHEMBL3710528 0.98 — —
SCHEMBL3710533 0.98 — —
SCHEMBL8382034 0.81 — —
SCHEMBL265673 0.81 — —
SCHEMBL27923260 0.80 HCAR2 (0.41) ALDH1A1LMNASMN1; SMN2TSHRGAA
SCHEMBL3192124 0.79 — —
SCHEMBL3192121 0.79 — —
SCHEMBL27941983 0.77 ALDH1A1 (0.54) NPSR1ALDH1A1LMNACYP2D6SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118055934-A PARG inhibitory compounds 福克斯治疗股份公司 2024-05-17 — — CN disclosed
EP-2751104-B1 COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS NOVARTIS AG (CH) 2019-09-25 — — EP disclosed
EP-2751102-B1 COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS NOVARTIS AG (CH) 2019-03-27 — — EP disclosed
US-9199981-B2 Compounds and compositions as C-kit kinase inhibitors NOVARTIS AG (CH) 2015-12-01 — — US disclosed
US-9023839-B2 Compounds and compositions as c-kit kinase inhibitors IRM LLC (BM) 2015-05-05 — — US disclosed
US-20150051206-A1 COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS IRM LLC (BM) 2015-02-19 — — US disclosed
US-20150011508-A1 COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS IRM LLC (BM) 2015-01-08 — — US disclosed
US-20140228347-A1 COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS IRM LLC (BM) 2014-08-14 — — US disclosed
EP-2751105-A1 COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS IRM LLC (BM) 2014-07-09 — — EP disclosed
EP-2751103-A1 COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS IRM LLC (BM) 2014-07-09 — — EP disclosed
EP-2751102-A1 COMPOUNDS AND COMPOSITIONS AS c-KIT KINASE INHIBITORS IRM LLC (BM) 2014-07-09 — — EP disclosed
US-8754071-B2 Compounds and compositions as c-kit kinase inhibitors NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2014-06-17 — — US disclosed
US-20140031333-A1 COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS IRM LLC (BM) 2014-01-30 — — US disclosed
US-8569283-B2 Compounds and compositions as c-Kit kinase inhibitors IRM LLC (BM) 2013-10-29 — — US disclosed
WO-2013033116-A1 COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS IRM LLC (BM) 2013-03-07 — — WO disclosed
US-20130059832-A1 COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS IRM LLC (BM) 2013-03-07 — — US disclosed
WO-2013033203-A1 COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS IRM LLC (BM) 2013-03-07 — — WO disclosed
WO-2013033070-A1 COMPOUNDS AND COMPOSITIONS AS c-KIT KINASE INHIBITORS IRM LLC (BM) 2013-03-07 — — WO disclosed
WO-2013033167-A1 COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS IRM LLC (BM) 2013-03-07 — — WO disclosed
US-20130059846-A1 COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS IRM LLC (BM) 2013-03-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150051206-A1 COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS KIT, PDGFRA, PDGFRB NPSR1 3335/4885GLO1 3660/4885ALDH1A1 1538/4885
US-20140031333-A1 COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS KIT, PDGFRA, PDGFRB NPSR1 3335/4885GLO1 3660/4885ALDH1A1 1538/4885
US-20130059832-A1 COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS KIT, PDGFRA, PDGFRB NPSR1 3335/4885GLO1 3660/4885ALDH1A1 1538/4885
US-20150011508-A1 COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS KIT, PDGFRA, PDGFRB NPSR1 3037/4885GLO1 3493/4885ALDH1A1 1047/4885
US-20140228347-A1 COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS KIT, PDGFRA, PDGFRB NPSR1 3335/4885GLO1 3660/4885ALDH1A1 1538/4885
US-20130059846-A1 COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS KIT, PDGFRA, PDGFRB NPSR1 3335/4885GLO1 3660/4885ALDH1A1 1538/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.